BioLife Solutions, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thomas Flaten from Lake Street downgraded the rating on the stock to a Hold and gave it a $31.00 price target.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Thomas Flaten has given his Hold rating due to a combination of factors tied primarily to the announced acquisition by Repligen. With Repligen agreeing to purchase BioLife at $31 per share in a cash-and-stock transaction, the stock price is now effectively bracketed by the deal terms, leaving only modest potential appreciation from the current trading level and limiting further upside for standalone investors.

Flaten’s revised $31 price target simply matches the agreed acquisition price, down from his prior $33 target that was based on a higher EV/revenue multiple and independent growth forecasts. While he acknowledges BioLife’s successful strategic refocus on high-margin, recurring biopreservation media and solid recent revenue momentum, the pending transaction, required approvals, and the lack of additional catalysts as a standalone company support a neutral stance rather than a more constructive rating.